Satish Garg
Concepts (652)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypoglycemic Agents | 93 | 2023 | 1013 | 16.260 |
Why?
| Diabetes Mellitus, Type 1 | 142 | 2023 | 3252 | 15.710 |
Why?
| Blood Glucose | 107 | 2023 | 1828 | 12.260 |
Why?
| Blood Glucose Self-Monitoring | 67 | 2023 | 505 | 12.220 |
Why?
| Insulin | 79 | 2023 | 2080 | 10.300 |
Why?
| Diabetes Mellitus, Type 2 | 55 | 2023 | 2096 | 9.170 |
Why?
| Diabetes Mellitus | 30 | 2023 | 900 | 7.530 |
Why?
| Hypoglycemia | 50 | 2023 | 387 | 7.220 |
Why?
| Insulin Infusion Systems | 37 | 2022 | 299 | 5.300 |
Why?
| Monitoring, Ambulatory | 17 | 2017 | 81 | 4.450 |
Why?
| Myometrium | 9 | 2021 | 35 | 4.360 |
Why?
| Buffaloes | 11 | 2021 | 12 | 4.320 |
Why?
| Periodicals as Topic | 7 | 2020 | 181 | 3.390 |
Why?
| Hyperglycemia | 17 | 2022 | 292 | 3.260 |
Why?
| Biosimilar Pharmaceuticals | 6 | 2020 | 25 | 3.220 |
Why?
| Insulin Glargine | 25 | 2022 | 73 | 3.210 |
Why?
| Diabetic Ketoacidosis | 11 | 2022 | 159 | 3.110 |
Why?
| Pregnancy in Diabetics | 13 | 2023 | 82 | 2.990 |
Why?
| Uterine Contraction | 8 | 2021 | 17 | 2.920 |
Why?
| Spermatozoa | 7 | 2021 | 84 | 2.840 |
Why?
| Dog Diseases | 4 | 2021 | 41 | 2.680 |
Why?
| Insulin Lispro | 14 | 2022 | 35 | 2.560 |
Why?
| Insulin Aspart | 9 | 2020 | 26 | 2.500 |
Why?
| Biomedical Technology | 5 | 2023 | 40 | 2.320 |
Why?
| Insulin, Long-Acting | 21 | 2022 | 53 | 2.250 |
Why?
| Cytokines | 7 | 2021 | 1841 | 2.210 |
Why?
| Glycosides | 9 | 2023 | 33 | 2.190 |
Why?
| Mercury | 3 | 2021 | 29 | 2.060 |
Why?
| Humans | 196 | 2023 | 114699 | 2.030 |
Why?
| Sperm Motility | 6 | 2021 | 26 | 1.790 |
Why?
| Telemedicine | 6 | 2021 | 662 | 1.740 |
Why?
| Plant Extracts | 5 | 2019 | 154 | 1.720 |
Why?
| Sperm Capacitation | 6 | 2021 | 12 | 1.720 |
Why?
| Antioxidants | 5 | 2020 | 530 | 1.600 |
Why?
| Sepsis | 3 | 2023 | 509 | 1.500 |
Why?
| Female | 111 | 2023 | 59520 | 1.480 |
Why?
| Calcium | 8 | 2021 | 1108 | 1.470 |
Why?
| Animals | 50 | 2023 | 31708 | 1.440 |
Why?
| Theileriasis | 2 | 2020 | 2 | 1.420 |
Why?
| Adult | 80 | 2022 | 30553 | 1.380 |
Why?
| Mite Infestations | 2 | 2020 | 2 | 1.370 |
Why?
| Injections, Subcutaneous | 11 | 2021 | 134 | 1.360 |
Why?
| Pancreas, Artificial | 4 | 2020 | 68 | 1.350 |
Why?
| Male | 93 | 2022 | 55606 | 1.330 |
Why?
| rho-Associated Kinases | 3 | 2021 | 80 | 1.280 |
Why?
| Calcium Signaling | 3 | 2021 | 217 | 1.280 |
Why?
| Vasoconstriction | 2 | 2022 | 177 | 1.280 |
Why?
| Postprandial Period | 5 | 2020 | 87 | 1.240 |
Why?
| Pre-Eclampsia | 10 | 2023 | 165 | 1.220 |
Why?
| Trace Elements | 2 | 2020 | 45 | 1.200 |
Why?
| Cattle | 8 | 2020 | 920 | 1.200 |
Why?
| Diabetes Complications | 5 | 2020 | 211 | 1.150 |
Why?
| Drug Therapy, Combination | 14 | 2021 | 951 | 1.140 |
Why?
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 245 | 1.130 |
Why?
| Trypanosomiasis | 2 | 2017 | 5 | 1.130 |
Why?
| Pandemics | 5 | 2022 | 1320 | 1.100 |
Why?
| Insulin, Isophane | 6 | 2017 | 18 | 1.100 |
Why?
| Rats, Wistar | 11 | 2020 | 368 | 1.100 |
Why?
| Dermatitis, Atopic | 2 | 2021 | 307 | 1.090 |
Why?
| Drugs, Investigational | 2 | 2017 | 30 | 1.040 |
Why?
| Protein Kinase C | 2 | 2018 | 273 | 1.020 |
Why?
| Middle Aged | 49 | 2022 | 26738 | 1.010 |
Why?
| Histamine | 2 | 2017 | 56 | 1.000 |
Why?
| Pneumonia, Viral | 2 | 2020 | 338 | 0.970 |
Why?
| Coronavirus Infections | 2 | 2020 | 330 | 0.960 |
Why?
| Lead | 2 | 2016 | 43 | 0.960 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 44 | 0.930 |
Why?
| Biomedical Research | 8 | 2017 | 585 | 0.920 |
Why?
| Uterus | 6 | 2021 | 192 | 0.910 |
Why?
| Monitoring, Physiologic | 6 | 2023 | 249 | 0.890 |
Why?
| Cross-Over Studies | 10 | 2020 | 440 | 0.850 |
Why?
| Spleen | 3 | 2020 | 487 | 0.830 |
Why?
| Angiotensin II | 1 | 2023 | 87 | 0.830 |
Why?
| Pregnancy | 23 | 2023 | 5520 | 0.810 |
Why?
| Glucagon-Like Peptide 1 | 3 | 2013 | 101 | 0.800 |
Why?
| Dinoprost | 2 | 2021 | 31 | 0.800 |
Why?
| Receptor, Notch3 | 1 | 2022 | 3 | 0.800 |
Why?
| Sulfones | 2 | 2020 | 97 | 0.790 |
Why?
| Benzamides | 2 | 2020 | 169 | 0.790 |
Why?
| Aorta | 2 | 2022 | 386 | 0.770 |
Why?
| Reproducibility of Results | 13 | 2022 | 2765 | 0.760 |
Why?
| Treatment Outcome | 20 | 2022 | 9088 | 0.760 |
Why?
| Dose-Response Relationship, Drug | 14 | 2020 | 1842 | 0.750 |
Why?
| Nifedipine | 6 | 2021 | 29 | 0.750 |
Why?
| Administration, Inhalation | 4 | 2018 | 641 | 0.750 |
Why?
| Arterial Pressure | 1 | 2022 | 99 | 0.750 |
Why?
| Intermediate Filament Proteins | 1 | 2021 | 65 | 0.740 |
Why?
| Dogs | 5 | 2021 | 334 | 0.740 |
Why?
| TRPC Cation Channels | 2 | 2021 | 11 | 0.740 |
Why?
| Calcium Channel Blockers | 6 | 2021 | 114 | 0.740 |
Why?
| Type C Phospholipases | 2 | 2018 | 65 | 0.740 |
Why?
| Insulin Antibodies | 2 | 2020 | 102 | 0.730 |
Why?
| Trypanosoma | 2 | 2017 | 7 | 0.730 |
Why?
| Mitochondrial Membranes | 1 | 2021 | 32 | 0.720 |
Why?
| Biopolymers | 1 | 2020 | 26 | 0.720 |
Why?
| Gelatin | 1 | 2020 | 36 | 0.720 |
Why?
| Endometritis | 2 | 2017 | 4 | 0.710 |
Why?
| Theileria annulata | 1 | 2020 | 1 | 0.710 |
Why?
| Chitosan | 1 | 2020 | 28 | 0.710 |
Why?
| Protein Precursors | 1 | 2021 | 119 | 0.710 |
Why?
| Young Adult | 24 | 2022 | 10471 | 0.710 |
Why?
| Copper Sulfate | 1 | 2020 | 6 | 0.700 |
Why?
| Diabetic Angiopathies | 6 | 2013 | 244 | 0.700 |
Why?
| Selenium | 1 | 2020 | 31 | 0.700 |
Why?
| Cattle Diseases | 1 | 2020 | 15 | 0.700 |
Why?
| Patient Education as Topic | 6 | 2020 | 680 | 0.700 |
Why?
| Exophthalmos | 1 | 2020 | 19 | 0.700 |
Why?
| Mutagens | 1 | 2020 | 17 | 0.700 |
Why?
| Sodium-Glucose Transporter 1 | 2 | 2017 | 10 | 0.700 |
Why?
| Betacoronavirus | 2 | 2020 | 250 | 0.700 |
Why?
| Sulfonylurea Compounds | 2 | 2018 | 44 | 0.690 |
Why?
| Calcium Channels | 2 | 2018 | 145 | 0.690 |
Why?
| Signal Transduction | 5 | 2022 | 4515 | 0.690 |
Why?
| Oleic Acid | 1 | 2020 | 30 | 0.680 |
Why?
| Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.680 |
Why?
| Polyalthia | 1 | 2019 | 1 | 0.680 |
Why?
| Mites | 1 | 2019 | 3 | 0.680 |
Why?
| Infusions, Subcutaneous | 4 | 2016 | 19 | 0.670 |
Why?
| Newcastle disease virus | 1 | 2019 | 17 | 0.670 |
Why?
| Peroxidase | 2 | 2017 | 163 | 0.670 |
Why?
| Isoproterenol | 1 | 2020 | 106 | 0.670 |
Why?
| Down-Regulation | 1 | 2022 | 594 | 0.660 |
Why?
| Oxidative Stress | 4 | 2020 | 1076 | 0.660 |
Why?
| Aged | 24 | 2022 | 19074 | 0.650 |
Why?
| Potassium Channels | 1 | 2020 | 121 | 0.650 |
Why?
| Adolescent | 30 | 2022 | 17853 | 0.640 |
Why?
| Endocannabinoids | 2 | 2019 | 36 | 0.640 |
Why?
| Toll-Like Receptors | 1 | 2020 | 167 | 0.640 |
Why?
| Uterine Artery | 1 | 2019 | 67 | 0.630 |
Why?
| Biosensing Techniques | 2 | 2018 | 100 | 0.620 |
Why?
| Wound Healing | 1 | 2020 | 258 | 0.620 |
Why?
| Mercuric Chloride | 1 | 2018 | 2 | 0.620 |
Why?
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 15 | 0.610 |
Why?
| Glucose | 5 | 2022 | 897 | 0.610 |
Why?
| Vasodilation | 2 | 2019 | 419 | 0.610 |
Why?
| Voltage-Gated Sodium Channels | 1 | 2017 | 4 | 0.600 |
Why?
| Tocolysis | 1 | 2017 | 4 | 0.590 |
Why?
| Mitochondria | 2 | 2021 | 747 | 0.590 |
Why?
| Eucalyptus | 1 | 2017 | 5 | 0.590 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2018 | 48 | 0.590 |
Why?
| Ethanolamines | 1 | 2017 | 19 | 0.590 |
Why?
| Oxytocin | 2 | 2016 | 45 | 0.590 |
Why?
| KATP Channels | 1 | 2017 | 16 | 0.590 |
Why?
| Immunoglobulin E | 1 | 2019 | 314 | 0.590 |
Why?
| Endothelium, Vascular | 3 | 2019 | 847 | 0.580 |
Why?
| Self Care | 4 | 2013 | 349 | 0.580 |
Why?
| Norepinephrine | 1 | 2018 | 201 | 0.580 |
Why?
| Interleukins | 1 | 2019 | 236 | 0.570 |
Why?
| Hydrogen Sulfide | 1 | 2017 | 40 | 0.570 |
Why?
| Reactive Oxygen Species | 1 | 2020 | 531 | 0.570 |
Why?
| Insulins | 1 | 2018 | 32 | 0.570 |
Why?
| Coinfection | 1 | 2018 | 120 | 0.560 |
Why?
| Syringes | 3 | 2013 | 41 | 0.560 |
Why?
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 4 | 0.560 |
Why?
| Cadmium | 1 | 2017 | 58 | 0.560 |
Why?
| Therapies, Investigational | 1 | 2017 | 14 | 0.550 |
Why?
| Inflammation Mediators | 1 | 2020 | 477 | 0.550 |
Why?
| Minerals | 1 | 2016 | 37 | 0.540 |
Why?
| Muscle Relaxation | 1 | 2016 | 19 | 0.540 |
Why?
| Cholinesterases | 1 | 2016 | 6 | 0.540 |
Why?
| Diffusion of Innovation | 1 | 2017 | 93 | 0.530 |
Why?
| Calcium Channels, L-Type | 1 | 2017 | 107 | 0.530 |
Why?
| Ambulatory Care Facilities | 2 | 2023 | 213 | 0.520 |
Why?
| Consensus | 7 | 2023 | 537 | 0.520 |
Why?
| Myocytes, Cardiac | 1 | 2020 | 449 | 0.510 |
Why?
| Receptors, Adrenergic, beta | 1 | 2016 | 127 | 0.510 |
Why?
| Disposable Equipment | 2 | 2013 | 15 | 0.500 |
Why?
| Vitamins | 1 | 2016 | 151 | 0.500 |
Why?
| Drug Delivery Systems | 2 | 2018 | 296 | 0.490 |
Why?
| Rats | 7 | 2020 | 4958 | 0.490 |
Why?
| Insulin Detemir | 5 | 2017 | 8 | 0.480 |
Why?
| Gene Expression | 1 | 2020 | 1421 | 0.480 |
Why?
| Glucagon | 2 | 2022 | 92 | 0.460 |
Why?
| Drug Administration Schedule | 8 | 2017 | 718 | 0.460 |
Why?
| Antiviral Agents | 1 | 2019 | 645 | 0.450 |
Why?
| Withania | 1 | 2013 | 3 | 0.450 |
Why?
| Double-Blind Method | 8 | 2022 | 1660 | 0.440 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2013 | 41 | 0.440 |
Why?
| Weight Gain | 5 | 2018 | 453 | 0.430 |
Why?
| Extracellular Fluid | 1 | 2013 | 30 | 0.430 |
Why?
| Glucosides | 3 | 2019 | 36 | 0.430 |
Why?
| Nervous System Diseases | 1 | 2016 | 256 | 0.430 |
Why?
| History, 21st Century | 3 | 2020 | 159 | 0.420 |
Why?
| Chlorpyrifos | 1 | 2013 | 6 | 0.420 |
Why?
| Portal Vein | 1 | 2013 | 76 | 0.420 |
Why?
| Benzhydryl Compounds | 3 | 2019 | 60 | 0.420 |
Why?
| Myocardial Infarction | 1 | 2020 | 927 | 0.420 |
Why?
| Microsomes, Liver | 1 | 2013 | 55 | 0.420 |
Why?
| Time Factors | 12 | 2021 | 6116 | 0.420 |
Why?
| Arsenic | 1 | 2013 | 37 | 0.410 |
Why?
| Pregnancy Outcome | 3 | 2023 | 337 | 0.400 |
Why?
| Pyrazines | 1 | 2013 | 71 | 0.400 |
Why?
| Prevalence | 8 | 2020 | 2251 | 0.400 |
Why?
| Ascorbic Acid | 1 | 2013 | 110 | 0.400 |
Why?
| Biomarkers | 11 | 2023 | 3408 | 0.390 |
Why?
| Patient Preference | 1 | 2013 | 167 | 0.380 |
Why?
| Tocolytic Agents | 2 | 2017 | 15 | 0.380 |
Why?
| Triazoles | 1 | 2013 | 131 | 0.380 |
Why?
| United States | 15 | 2021 | 12186 | 0.380 |
Why?
| Needles | 1 | 2011 | 49 | 0.380 |
Why?
| Clinical Trials as Topic | 7 | 2022 | 932 | 0.370 |
Why?
| Registries | 5 | 2020 | 1768 | 0.370 |
Why?
| Goats | 2 | 2021 | 26 | 0.370 |
Why?
| Adrenergic beta-Agonists | 2 | 2017 | 126 | 0.360 |
Why?
| History, 20th Century | 3 | 2019 | 264 | 0.360 |
Why?
| Blood Chemical Analysis | 2 | 2017 | 90 | 0.350 |
Why?
| Water Pollutants, Chemical | 1 | 2013 | 175 | 0.340 |
Why?
| Acetylcholine | 3 | 2019 | 166 | 0.340 |
Why?
| Calibration | 3 | 2018 | 125 | 0.330 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2022 | 157 | 0.330 |
Why?
| China | 4 | 2020 | 161 | 0.330 |
Why?
| Pregnancy Trimester, First | 3 | 2020 | 125 | 0.330 |
Why?
| Research Design | 6 | 2015 | 928 | 0.330 |
Why?
| Health Care Costs | 4 | 2016 | 381 | 0.320 |
Why?
| Intention to Treat Analysis | 3 | 2017 | 68 | 0.320 |
Why?
| 4-Aminopyridine | 2 | 2020 | 21 | 0.320 |
Why?
| Plant Leaves | 3 | 2019 | 110 | 0.320 |
Why?
| Reference Values | 6 | 2023 | 743 | 0.320 |
Why?
| Prediabetic State | 1 | 2011 | 219 | 0.310 |
Why?
| alpha-Tocopherol | 2 | 2020 | 25 | 0.310 |
Why?
| Software | 3 | 2013 | 530 | 0.310 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 1481 | 0.310 |
Why?
| Computer Systems | 2 | 2018 | 45 | 0.300 |
Why?
| Animals, Newborn | 2 | 2020 | 778 | 0.300 |
Why?
| Prospective Studies | 12 | 2022 | 6220 | 0.290 |
Why?
| Child | 11 | 2022 | 18420 | 0.290 |
Why?
| Veratridine | 2 | 2017 | 7 | 0.290 |
Why?
| Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.280 |
Why?
| Equipment Design | 4 | 2010 | 508 | 0.270 |
Why?
| Hypertension | 4 | 2011 | 1056 | 0.270 |
Why?
| United States Food and Drug Administration | 3 | 2018 | 172 | 0.270 |
Why?
| Nitric Oxide | 3 | 2022 | 823 | 0.270 |
Why?
| Exercise | 2 | 2014 | 1644 | 0.270 |
Why?
| Vasodilator Agents | 2 | 2019 | 302 | 0.260 |
Why?
| Journal Impact Factor | 2 | 2020 | 27 | 0.260 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 149 | 0.260 |
Why?
| Ruthenium Red | 2 | 2016 | 8 | 0.250 |
Why?
| Albuminuria | 3 | 2017 | 164 | 0.250 |
Why?
| Blotting, Western | 3 | 2017 | 1147 | 0.250 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2021 | 1140 | 0.250 |
Why?
| Algorithms | 5 | 2018 | 1470 | 0.250 |
Why?
| Tissue Culture Techniques | 2 | 2017 | 66 | 0.250 |
Why?
| Lipoproteins | 2 | 2019 | 159 | 0.250 |
Why?
| Fasting | 1 | 2006 | 241 | 0.250 |
Why?
| Copper | 2 | 2016 | 100 | 0.250 |
Why?
| Phenylephrine | 2 | 2016 | 71 | 0.240 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 10 | 0.240 |
Why?
| Body Weight | 7 | 2020 | 869 | 0.240 |
Why?
| Mass Screening | 1 | 2011 | 1005 | 0.240 |
Why?
| Phosphorylation | 2 | 2020 | 1569 | 0.230 |
Why?
| Pyrazoles | 2 | 2018 | 362 | 0.230 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 32 | 0.230 |
Why?
| Cardiovascular Diseases | 2 | 2013 | 1727 | 0.230 |
Why?
| Calcinosis | 4 | 2010 | 242 | 0.230 |
Why?
| Dietary Supplements | 2 | 2018 | 460 | 0.220 |
Why?
| Aged, 80 and over | 3 | 2022 | 6347 | 0.220 |
Why?
| Uridine Diphosphate | 1 | 2023 | 2 | 0.220 |
Why?
| Equipment Failure | 2 | 2018 | 106 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2021 | 1214 | 0.210 |
Why?
| Mice | 5 | 2023 | 14871 | 0.210 |
Why?
| Endocrinology | 2 | 2016 | 70 | 0.210 |
Why?
| Receptors, Glucagon | 1 | 2022 | 23 | 0.200 |
Why?
| Vitamin D-Binding Protein | 2 | 2020 | 13 | 0.200 |
Why?
| Safety | 3 | 2009 | 298 | 0.200 |
Why?
| Child, Preschool | 5 | 2022 | 9118 | 0.200 |
Why?
| 3-Hydroxybutyric Acid | 2 | 2021 | 14 | 0.200 |
Why?
| Mobile Applications | 2 | 2021 | 141 | 0.200 |
Why?
| Ketosis | 1 | 2021 | 12 | 0.190 |
Why?
| Risk Factors | 7 | 2021 | 8632 | 0.190 |
Why?
| Reference Standards | 4 | 2017 | 159 | 0.190 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2019 | 55 | 0.190 |
Why?
| Illinois | 1 | 2021 | 37 | 0.190 |
Why?
| Immunization, Passive | 1 | 2021 | 73 | 0.190 |
Why?
| Los Angeles | 1 | 2021 | 56 | 0.180 |
Why?
| New York City | 1 | 2021 | 70 | 0.180 |
Why?
| Patient Isolation | 1 | 2021 | 18 | 0.180 |
Why?
| Disease Models, Animal | 2 | 2020 | 3535 | 0.180 |
Why?
| Patient Satisfaction | 3 | 2015 | 578 | 0.180 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 57 | 0.180 |
Why?
| Incidence | 3 | 2017 | 2313 | 0.180 |
Why?
| Interleukin-13 | 1 | 2021 | 122 | 0.180 |
Why?
| Practice Guidelines as Topic | 3 | 2019 | 1395 | 0.180 |
Why?
| Progesterone | 2 | 2019 | 232 | 0.180 |
Why?
| Micronucleus Tests | 1 | 2020 | 4 | 0.180 |
Why?
| Antigens, Viral | 1 | 2021 | 176 | 0.180 |
Why?
| Comet Assay | 1 | 2020 | 18 | 0.180 |
Why?
| Skin Diseases, Parasitic | 1 | 2020 | 1 | 0.170 |
Why?
| Chromium | 1 | 2020 | 12 | 0.170 |
Why?
| Uncoupling Protein 2 | 1 | 2020 | 8 | 0.170 |
Why?
| Cardiotoxicity | 1 | 2020 | 27 | 0.170 |
Why?
| Income | 1 | 2021 | 167 | 0.170 |
Why?
| Curcumin | 1 | 2020 | 28 | 0.170 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 22 | 0.170 |
Why?
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.170 |
Why?
| Transforming Growth Factor beta1 | 1 | 2020 | 153 | 0.170 |
Why?
| Glycemic Index | 2 | 2009 | 21 | 0.170 |
Why?
| Cyclooxygenase 1 | 1 | 2019 | 20 | 0.170 |
Why?
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 8 | 0.170 |
Why?
| Vero Cells | 1 | 2019 | 63 | 0.170 |
Why?
| Virus Internalization | 1 | 2019 | 40 | 0.170 |
Why?
| Lipid Peroxidation | 1 | 2020 | 139 | 0.170 |
Why?
| Diabetes, Gestational | 1 | 2023 | 281 | 0.170 |
Why?
| Haptoglobins | 1 | 2019 | 47 | 0.160 |
Why?
| Liver Cirrhosis | 1 | 2021 | 227 | 0.160 |
Why?
| Host-Parasite Interactions | 1 | 2020 | 94 | 0.160 |
Why?
| Canagliflozin | 1 | 2019 | 8 | 0.160 |
Why?
| Area Under Curve | 3 | 2015 | 274 | 0.160 |
Why?
| Immunity, Cellular | 2 | 2018 | 248 | 0.160 |
Why?
| Tyrosine | 1 | 2020 | 214 | 0.160 |
Why?
| Adamantane | 1 | 2019 | 16 | 0.160 |
Why?
| California | 1 | 2020 | 353 | 0.160 |
Why?
| Vitamin D | 2 | 2020 | 341 | 0.160 |
Why?
| Dipeptides | 1 | 2019 | 48 | 0.160 |
Why?
| Ion Channels | 1 | 2019 | 123 | 0.160 |
Why?
| TRPV Cation Channels | 1 | 2019 | 31 | 0.160 |
Why?
| Congresses as Topic | 2 | 2020 | 195 | 0.160 |
Why?
| Sensitivity and Specificity | 4 | 2009 | 1693 | 0.150 |
Why?
| Meals | 1 | 2020 | 104 | 0.150 |
Why?
| Self Efficacy | 1 | 2002 | 355 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 28 | 0.150 |
Why?
| Patient Care Planning | 1 | 2019 | 139 | 0.150 |
Why?
| Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| Blood Pressure | 3 | 2021 | 1538 | 0.150 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 663 | 0.150 |
Why?
| Organ Culture Techniques | 1 | 2018 | 140 | 0.150 |
Why?
| Aminooxyacetic Acid | 1 | 2017 | 1 | 0.150 |
Why?
| Sodium Channel Agonists | 1 | 2017 | 1 | 0.150 |
Why?
| Biomechanical Phenomena | 1 | 2021 | 669 | 0.150 |
Why?
| Administration, Oral | 2 | 2017 | 728 | 0.150 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 498 | 0.150 |
Why?
| Receptors, Adrenergic, beta-3 | 1 | 2017 | 3 | 0.150 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| Injections | 1 | 2018 | 159 | 0.150 |
Why?
| International Agencies | 1 | 2017 | 30 | 0.150 |
Why?
| Longitudinal Studies | 6 | 2020 | 2387 | 0.150 |
Why?
| Serum Amyloid A Protein | 1 | 2017 | 29 | 0.150 |
Why?
| Hemoglobin A | 1 | 2017 | 21 | 0.150 |
Why?
| Malondialdehyde | 1 | 2017 | 28 | 0.150 |
Why?
| Antibodies, Viral | 1 | 2021 | 520 | 0.150 |
Why?
| Equivalence Trials as Topic | 1 | 2017 | 6 | 0.150 |
Why?
| Methanol | 1 | 2017 | 29 | 0.150 |
Why?
| Analysis of Variance | 1 | 2020 | 1226 | 0.150 |
Why?
| DNA Damage | 1 | 2020 | 351 | 0.150 |
Why?
| Glyburide | 1 | 2017 | 35 | 0.150 |
Why?
| Toll-Like Receptor 9 | 1 | 2017 | 30 | 0.150 |
Why?
| Alkynes | 1 | 2017 | 53 | 0.140 |
Why?
| Least-Squares Analysis | 1 | 2017 | 70 | 0.140 |
Why?
| Protein Carbonylation | 1 | 2017 | 51 | 0.140 |
Why?
| Data Interpretation, Statistical | 1 | 2019 | 321 | 0.140 |
Why?
| Patient Compliance | 2 | 2013 | 525 | 0.140 |
Why?
| Adipokines | 1 | 2017 | 42 | 0.140 |
Why?
| HLA-DQ Antigens | 1 | 2018 | 174 | 0.140 |
Why?
| Phytotherapy | 1 | 2017 | 66 | 0.140 |
Why?
| Solvents | 1 | 2017 | 104 | 0.140 |
Why?
| Coronary Artery Disease | 3 | 2010 | 607 | 0.140 |
Why?
| Propanolamines | 1 | 2017 | 90 | 0.140 |
Why?
| Patient Dropouts | 1 | 2017 | 66 | 0.140 |
Why?
| Clinical Protocols | 1 | 2018 | 233 | 0.140 |
Why?
| Lung | 1 | 2009 | 3561 | 0.140 |
Why?
| Antihypertensive Agents | 3 | 2012 | 429 | 0.140 |
Why?
| Islet Amyloid Polypeptide | 3 | 2013 | 47 | 0.140 |
Why?
| Immunization | 1 | 2019 | 397 | 0.140 |
Why?
| Pilot Projects | 2 | 2018 | 1373 | 0.140 |
Why?
| Piperidines | 1 | 2018 | 160 | 0.140 |
Why?
| Glycine | 1 | 2017 | 152 | 0.140 |
Why?
| Antigen Presentation | 1 | 2018 | 188 | 0.140 |
Why?
| Socioeconomic Factors | 1 | 2021 | 1079 | 0.140 |
Why?
| Anniversaries and Special Events | 1 | 2017 | 12 | 0.140 |
Why?
| Uric Acid | 1 | 2018 | 148 | 0.140 |
Why?
| Cyclooxygenase 2 | 1 | 2017 | 164 | 0.140 |
Why?
| Cell Survival | 1 | 2020 | 1021 | 0.140 |
Why?
| Computer-Aided Design | 1 | 2017 | 38 | 0.140 |
Why?
| Fatty Acids, Nonesterified | 1 | 2017 | 151 | 0.140 |
Why?
| Combined Modality Therapy | 2 | 2017 | 1121 | 0.140 |
Why?
| Furans | 1 | 2016 | 22 | 0.140 |
Why?
| Up-Regulation | 1 | 2020 | 808 | 0.140 |
Why?
| Indicators and Reagents | 1 | 2016 | 99 | 0.140 |
Why?
| Cysteine | 1 | 2017 | 171 | 0.140 |
Why?
| Antibody Formation | 1 | 2018 | 266 | 0.140 |
Why?
| Oleaceae | 1 | 2016 | 1 | 0.140 |
Why?
| In Vitro Techniques | 2 | 2016 | 1016 | 0.140 |
Why?
| Comorbidity | 1 | 2021 | 1448 | 0.130 |
Why?
| Aniline Compounds | 1 | 2016 | 70 | 0.130 |
Why?
| Sympathomimetics | 1 | 2016 | 25 | 0.130 |
Why?
| Eating | 3 | 2009 | 344 | 0.130 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 447 | 0.130 |
Why?
| Estradiol | 1 | 2019 | 455 | 0.130 |
Why?
| Leptin | 2 | 2017 | 210 | 0.130 |
Why?
| Drug Hypersensitivity | 1 | 2017 | 83 | 0.130 |
Why?
| Membrane Potentials | 1 | 2016 | 248 | 0.130 |
Why?
| Forecasting | 2 | 2016 | 330 | 0.130 |
Why?
| Amyloid | 2 | 2007 | 80 | 0.130 |
Why?
| Vascular Stiffness | 1 | 2021 | 407 | 0.130 |
Why?
| Testis | 1 | 2016 | 133 | 0.130 |
Why?
| Drug Design | 1 | 2017 | 148 | 0.130 |
Why?
| Moringa oleifera | 1 | 2015 | 1 | 0.130 |
Why?
| RNA, Messenger | 1 | 2023 | 2553 | 0.130 |
Why?
| Incretins | 1 | 2015 | 15 | 0.130 |
Why?
| Imidazoles | 1 | 2016 | 208 | 0.130 |
Why?
| Interleukin-10 | 1 | 2017 | 299 | 0.130 |
Why?
| Body Mass Index | 5 | 2017 | 1959 | 0.130 |
Why?
| Postnatal Care | 1 | 2016 | 65 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 270 | 0.120 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 287 | 0.120 |
Why?
| Cells, Cultured | 2 | 2020 | 3886 | 0.120 |
Why?
| Diabetic Nephropathies | 1 | 2018 | 234 | 0.120 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 254 | 0.120 |
Why?
| Early Diagnosis | 2 | 2015 | 217 | 0.120 |
Why?
| Disease Management | 1 | 2019 | 560 | 0.120 |
Why?
| Self-Management | 1 | 2017 | 126 | 0.120 |
Why?
| Case-Control Studies | 2 | 2019 | 3003 | 0.120 |
Why?
| Inflammation | 1 | 2005 | 2480 | 0.120 |
Why?
| Materials Testing | 2 | 2017 | 337 | 0.120 |
Why?
| Vitamin D Deficiency | 2 | 2020 | 158 | 0.120 |
Why?
| Colorado | 2 | 2020 | 4100 | 0.120 |
Why?
| Cholesterol, HDL | 1 | 2015 | 183 | 0.120 |
Why?
| Estrenes | 1 | 2014 | 15 | 0.110 |
Why?
| Quality of Life | 5 | 2016 | 2353 | 0.110 |
Why?
| Pyrrolidinones | 1 | 2014 | 25 | 0.110 |
Why?
| Staphylococcus aureus | 1 | 2017 | 389 | 0.110 |
Why?
| Kidney Diseases | 1 | 2017 | 350 | 0.110 |
Why?
| Escherichia coli | 1 | 2017 | 720 | 0.110 |
Why?
| Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.110 |
Why?
| Organometallic Compounds | 1 | 2015 | 98 | 0.110 |
Why?
| Allylamine | 1 | 2013 | 7 | 0.110 |
Why?
| Bromocriptine | 1 | 2013 | 26 | 0.110 |
Why?
| Leadership | 1 | 2017 | 292 | 0.110 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 17 | 0.110 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2014 | 82 | 0.110 |
Why?
| Prenatal Care | 1 | 2016 | 253 | 0.110 |
Why?
| Age Factors | 2 | 2019 | 2894 | 0.110 |
Why?
| Staining and Labeling | 1 | 2014 | 134 | 0.110 |
Why?
| Catecholamines | 1 | 2013 | 94 | 0.110 |
Why?
| Immunohistochemistry | 1 | 2017 | 1629 | 0.110 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 750 | 0.110 |
Why?
| Cooperative Behavior | 1 | 2016 | 381 | 0.110 |
Why?
| Circadian Rhythm | 4 | 2015 | 356 | 0.110 |
Why?
| Oxidation-Reduction | 1 | 2016 | 923 | 0.110 |
Why?
| Immunologic Factors | 1 | 2015 | 220 | 0.110 |
Why?
| Coronary Disease | 2 | 2007 | 348 | 0.110 |
Why?
| Autoantibodies | 2 | 2018 | 1346 | 0.110 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 98 | 0.110 |
Why?
| T-Lymphocytes | 2 | 2018 | 1737 | 0.110 |
Why?
| Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.110 |
Why?
| Menopause | 1 | 2016 | 271 | 0.110 |
Why?
| Patient Selection | 2 | 2009 | 641 | 0.100 |
Why?
| Sitagliptin Phosphate | 1 | 2013 | 30 | 0.100 |
Why?
| Delayed-Action Preparations | 1 | 2013 | 159 | 0.100 |
Why?
| Insecticides | 1 | 2013 | 31 | 0.100 |
Why?
| Islets of Langerhans Transplantation | 1 | 2013 | 53 | 0.100 |
Why?
| Thiazolidinediones | 1 | 2013 | 142 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2019 | 2320 | 0.100 |
Why?
| Zinc | 1 | 2015 | 260 | 0.100 |
Why?
| Cell Proliferation | 2 | 2016 | 2187 | 0.100 |
Why?
| Drinking Water | 1 | 2013 | 64 | 0.100 |
Why?
| Internet | 1 | 2016 | 596 | 0.100 |
Why?
| Hospitalization | 1 | 2020 | 1752 | 0.090 |
Why?
| Self Administration | 1 | 2011 | 122 | 0.090 |
Why?
| Cohort Studies | 4 | 2019 | 4895 | 0.090 |
Why?
| Carotenoids | 1 | 2011 | 35 | 0.090 |
Why?
| Retrospective Studies | 5 | 2020 | 12555 | 0.090 |
Why?
| Swine | 1 | 2013 | 700 | 0.090 |
Why?
| Surveys and Questionnaires | 4 | 2014 | 4624 | 0.090 |
Why?
| Managed Care Programs | 1 | 2011 | 133 | 0.090 |
Why?
| Home Care Services | 1 | 2013 | 223 | 0.090 |
Why?
| Regression Analysis | 2 | 2010 | 945 | 0.090 |
Why?
| Metformin | 1 | 2013 | 276 | 0.090 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 299 | 0.090 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 28 | 0.090 |
Why?
| Drug Combinations | 1 | 2010 | 287 | 0.080 |
Why?
| Decision Making | 2 | 2013 | 782 | 0.080 |
Why?
| Physicians | 2 | 2017 | 772 | 0.080 |
Why?
| Disease Progression | 3 | 2012 | 2380 | 0.080 |
Why?
| Cross-Sectional Studies | 4 | 2015 | 4410 | 0.080 |
Why?
| Carcinogens | 1 | 2009 | 103 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 646 | 0.080 |
Why?
| Vital Capacity | 1 | 2009 | 255 | 0.080 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 2218 | 0.080 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 35 | 0.070 |
Why?
| Forced Expiratory Volume | 1 | 2009 | 475 | 0.070 |
Why?
| C-Reactive Protein | 2 | 2013 | 362 | 0.070 |
Why?
| Drug Costs | 1 | 2008 | 92 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| Norway | 2 | 2019 | 36 | 0.070 |
Why?
| Sheep | 1 | 2010 | 764 | 0.070 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2007 | 59 | 0.070 |
Why?
| Infant | 1 | 2020 | 7964 | 0.070 |
Why?
| Infusion Pumps, Implantable | 2 | 2004 | 20 | 0.070 |
Why?
| Nebulizers and Vaporizers | 1 | 2007 | 78 | 0.070 |
Why?
| Medication Adherence | 1 | 2011 | 536 | 0.070 |
Why?
| Australia | 2 | 2019 | 206 | 0.070 |
Why?
| Societies, Medical | 1 | 2010 | 664 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 72 | 0.070 |
Why?
| Risk Management | 2 | 2019 | 89 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 179 | 0.070 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 975 | 0.070 |
Why?
| Patient Acceptance of Health Care | 1 | 2012 | 681 | 0.070 |
Why?
| Creatinine | 2 | 2018 | 425 | 0.070 |
Why?
| Alprostadil | 1 | 2005 | 32 | 0.060 |
Why?
| Immunity, Humoral | 2 | 2016 | 112 | 0.060 |
Why?
| Organ Size | 2 | 2016 | 436 | 0.060 |
Why?
| Barium Compounds | 1 | 2004 | 7 | 0.060 |
Why?
| Terbutaline | 1 | 2004 | 7 | 0.060 |
Why?
| Potassium Chloride | 1 | 2004 | 32 | 0.060 |
Why?
| Glomerular Filtration Rate | 2 | 2018 | 604 | 0.060 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 2004 | 19 | 0.060 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2004 | 39 | 0.060 |
Why?
| Hyperlipidemias | 1 | 2005 | 121 | 0.060 |
Why?
| Dinoprostone | 1 | 2005 | 184 | 0.060 |
Why?
| Pulmonary Artery | 1 | 2010 | 1016 | 0.060 |
Why?
| Automation | 1 | 2004 | 74 | 0.060 |
Why?
| Capillaries | 1 | 2004 | 91 | 0.060 |
Why?
| Albuterol | 1 | 2004 | 102 | 0.060 |
Why?
| Homeostasis | 1 | 2007 | 573 | 0.060 |
Why?
| Chlorides | 1 | 2004 | 127 | 0.060 |
Why?
| Modems | 1 | 2003 | 1 | 0.050 |
Why?
| Primary Health Care | 1 | 2013 | 1514 | 0.050 |
Why?
| Glycation End Products, Advanced | 1 | 2023 | 57 | 0.050 |
Why?
| Fetal Macrosomia | 1 | 2003 | 58 | 0.050 |
Why?
| Transaminases | 1 | 2022 | 24 | 0.050 |
Why?
| Food | 1 | 2004 | 160 | 0.050 |
Why?
| Congenital Abnormalities | 1 | 2003 | 73 | 0.050 |
Why?
| Costs and Cost Analysis | 1 | 2003 | 196 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 4411 | 0.050 |
Why?
| Educational Status | 1 | 2004 | 412 | 0.050 |
Why?
| Insulin, Regular, Human | 1 | 2022 | 33 | 0.050 |
Why?
| Weight Loss | 2 | 2018 | 642 | 0.050 |
Why?
| Pregnant Women | 1 | 2023 | 131 | 0.050 |
Why?
| Brain | 1 | 2013 | 2371 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 3329 | 0.050 |
Why?
| Lipoproteins, LDL | 1 | 2022 | 128 | 0.050 |
Why?
| Ketone Bodies | 1 | 2021 | 15 | 0.050 |
Why?
| Age of Onset | 1 | 2003 | 446 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 31 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 52 | 0.050 |
Why?
| Breath Tests | 1 | 2021 | 82 | 0.050 |
Why?
| Ketones | 1 | 2021 | 44 | 0.050 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 373 | 0.050 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2021 | 82 | 0.050 |
Why?
| Learning | 1 | 2004 | 350 | 0.040 |
Why?
| Pregnancy Trimester, Second | 1 | 2020 | 66 | 0.040 |
Why?
| Gestational Age | 1 | 2003 | 760 | 0.040 |
Why?
| Birth Weight | 1 | 2003 | 440 | 0.040 |
Why?
| Self Concept | 1 | 2002 | 214 | 0.040 |
Why?
| Skin | 1 | 2004 | 655 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1125 | 0.040 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 35 | 0.040 |
Why?
| Vascular Resistance | 1 | 2021 | 337 | 0.040 |
Why?
| Acrosome Reaction | 1 | 2019 | 2 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 278 | 0.040 |
Why?
| Polyunsaturated Alkamides | 1 | 2019 | 7 | 0.040 |
Why?
| Data Accuracy | 1 | 2019 | 48 | 0.040 |
Why?
| Sleep | 2 | 2015 | 632 | 0.040 |
Why?
| Capsaicin | 1 | 2019 | 25 | 0.040 |
Why?
| Arachidonic Acids | 1 | 2019 | 56 | 0.040 |
Why?
| Immunoblotting | 1 | 2019 | 283 | 0.040 |
Why?
| Internationality | 1 | 2019 | 143 | 0.040 |
Why?
| Microscopy, Polarization | 1 | 2018 | 30 | 0.040 |
Why?
| Sodium | 1 | 2019 | 183 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 249 | 0.040 |
Why?
| Survival Rate | 1 | 2022 | 1644 | 0.040 |
Why?
| Osmolar Concentration | 1 | 2018 | 173 | 0.040 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.040 |
Why?
| Resistin | 1 | 2017 | 12 | 0.040 |
Why?
| Lipocalin-2 | 1 | 2017 | 61 | 0.040 |
Why?
| North America | 1 | 2018 | 256 | 0.040 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2017 | 60 | 0.040 |
Why?
| Lost to Follow-Up | 1 | 2017 | 22 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2020 | 616 | 0.030 |
Why?
| Seminiferous Tubules | 1 | 2016 | 10 | 0.030 |
Why?
| Semen | 1 | 2016 | 18 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2018 | 511 | 0.030 |
Why?
| Kidney | 1 | 2023 | 1188 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 2016 | 27 | 0.030 |
Why?
| Drug Resistance | 1 | 2017 | 158 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2018 | 555 | 0.030 |
Why?
| Physician-Patient Relations | 1 | 2020 | 462 | 0.030 |
Why?
| Research Personnel | 1 | 2017 | 149 | 0.030 |
Why?
| Models, Economic | 1 | 2016 | 48 | 0.030 |
Why?
| Cost Savings | 1 | 2016 | 74 | 0.030 |
Why?
| Adiponectin | 1 | 2017 | 213 | 0.030 |
Why?
| Edema | 1 | 2016 | 119 | 0.030 |
Why?
| Neoplasms | 1 | 2009 | 2097 | 0.030 |
Why?
| Polymorphism, Genetic | 2 | 2010 | 610 | 0.030 |
Why?
| Drug Monitoring | 1 | 2017 | 184 | 0.030 |
Why?
| Flowers | 1 | 2016 | 53 | 0.030 |
Why?
| Antibodies, Bacterial | 1 | 2016 | 119 | 0.030 |
Why?
| Equipment and Supplies | 1 | 2015 | 38 | 0.030 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2015 | 124 | 0.030 |
Why?
| Body Burden | 1 | 2015 | 5 | 0.030 |
Why?
| C-Peptide | 1 | 2015 | 138 | 0.030 |
Why?
| Communication | 1 | 2020 | 744 | 0.030 |
Why?
| Interleukin-2 | 1 | 2016 | 413 | 0.030 |
Why?
| Salmonella typhimurium | 1 | 2016 | 164 | 0.030 |
Why?
| Liver | 1 | 2022 | 1637 | 0.030 |
Why?
| Health Services Accessibility | 1 | 2020 | 763 | 0.030 |
Why?
| Academic Medical Centers | 1 | 2017 | 411 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 349 | 0.030 |
Why?
| Genotype | 2 | 2010 | 1760 | 0.030 |
Why?
| Electronic Health Records | 1 | 2020 | 800 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2020 | 833 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2015 | 167 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2016 | 544 | 0.030 |
Why?
| Testosterone | 1 | 2016 | 343 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 797 | 0.030 |
Why?
| Data Display | 1 | 2013 | 19 | 0.030 |
Why?
| E-Selectin | 1 | 2013 | 53 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 1950 | 0.030 |
Why?
| Chemokine CXCL10 | 1 | 2013 | 34 | 0.030 |
Why?
| Interleukin-6 | 1 | 2016 | 676 | 0.030 |
Why?
| Risk | 1 | 2015 | 812 | 0.030 |
Why?
| Bone and Bones | 1 | 2015 | 279 | 0.020 |
Why?
| Statistics as Topic | 1 | 2013 | 292 | 0.020 |
Why?
| Phenotype | 1 | 2019 | 2797 | 0.020 |
Why?
| Tetraethylammonium | 1 | 2011 | 15 | 0.020 |
Why?
| beta Carotene | 1 | 2011 | 18 | 0.020 |
Why?
| Vitamin A | 1 | 2011 | 52 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2015 | 766 | 0.020 |
Why?
| Expert Testimony | 1 | 2010 | 36 | 0.020 |
Why?
| Calcium Chloride | 1 | 2010 | 14 | 0.020 |
Why?
| Cholesterol | 1 | 2012 | 367 | 0.020 |
Why?
| Benzimidazoles | 1 | 2011 | 138 | 0.020 |
Why?
| Serotonin Antagonists | 1 | 2010 | 30 | 0.020 |
Why?
| Nitrites | 1 | 2010 | 75 | 0.020 |
Why?
| Intracellular Space | 1 | 2010 | 68 | 0.020 |
Why?
| Extracellular Space | 1 | 2010 | 116 | 0.020 |
Why?
| Potassium | 1 | 2010 | 128 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2017 | 2540 | 0.020 |
Why?
| Vasoconstrictor Agents | 1 | 2010 | 113 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2010 | 209 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 923 | 0.020 |
Why?
| Serotonin | 1 | 2010 | 292 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 10 | 0.020 |
Why?
| Long-Term Care | 1 | 2007 | 78 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 20 | 0.020 |
Why?
| Fatty Acids | 1 | 2010 | 381 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2007 | 88 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 51 | 0.020 |
Why?
| Peptides | 1 | 2011 | 848 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1621 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1796 | 0.020 |
Why?
| Fructosamine | 1 | 2005 | 14 | 0.020 |
Why?
| Hemoglobins | 1 | 2007 | 315 | 0.020 |
Why?
| Tomography, X-Ray Computed | 2 | 2003 | 2286 | 0.010 |
Why?
| Age Distribution | 1 | 2005 | 342 | 0.010 |
Why?
| Sex Distribution | 1 | 2005 | 337 | 0.010 |
Why?
| Hemoglobinuria | 1 | 2003 | 3 | 0.010 |
Why?
| Sex Characteristics | 1 | 2003 | 641 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 1841 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1072 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|